Form 4: Synaptogenix Director Acquires Stock Options

Bruce Bernstein, a director of Synaptogenix, Inc., acquired stock options on April 8, 2024.

Summary

• On April 8, 2024, Bruce Bernstein, a director of Synaptogenix, Inc., acquired stock options.
• The stock options grant the right to buy 800 shares of common stock at an exercise price of $5.39.
• The options vest after one year of service from April 8, 2024, and expire on April 8, 2034.
• Following the transaction, Bernstein directly owns 800 derivative securities.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It reflects a standard transaction of stock options being granted to a director, which is a common practice.

Positives

• The acquisition of stock options by a director could be seen as a positive sign, indicating confidence in the company's future performance.

Industry Context

This is a standard practice for incentivizing company directors and aligning their interests with those of shareholders.

Comparison to Industry Standards

• Stock option grants to directors are a common practice in the pharmaceutical industry to incentivize performance and align interests with shareholders.
• The vesting schedule of one year is fairly standard.
• The exercise price is set at $5.39.

Stakeholder Impact

• The granting of stock options to a director can align their interests with those of shareholders, potentially leading to decisions that benefit the company's long-term value.

Key Dates

Keywords

Synaptogenix, Director, Stock Options, Acquisition, Bernstein, SNPX, Form 4